BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS ... - Marketscreener.com
BCLI Stock | USD 1.51 0.09 5.63% |
Under 63% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS ... Marketscreener.com
Read at news.google.com
Brainstorm Cell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Brainstorm Cell Fundamental Analysis
We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Brainstorm Cell is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Brainstorm Cell Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.
Peers
Brainstorm Cell Related Equities
TRVI | Trevi Therapeutics | 44.58 | ||||
PASG | Passage Bio | 2.63 | ||||
INZY | Inozyme Pharma | 0.68 | ||||
CRVS | Corvus Pharmaceuticals | 0.37 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
TERN | Terns Pharmaceuticals | 1.64 | ||||
CELC | Celcuity LLC | 1.87 | ||||
HCWB | HCW Biologics | 2.50 | ||||
DAWN | Day One | 2.66 | ||||
MREO | Mereo BioPharma | 3.37 | ||||
CKPT | Checkpoint Therapeutics | 4.52 | ||||
ANTX | AN2 Therapeutics | 4.52 | ||||
EWTX | Edgewise Therapeutics | 5.54 | ||||
CNTB | Connect Biopharma | 6.50 | ||||
ALDX | Aldeyra | 6.70 | ||||
GBIO | Generation Bio | 7.03 | ||||
HOWL | Werewolf Therapeutics | 7.57 | ||||
CUE | Cue Biopharma | 7.89 | ||||
CCCC | C4 Therapeutics | 8.28 | ||||
GRI | GRI Bio | 8.92 | ||||
BCAB | Bioatla | 11.18 | ||||
XFOR | X4 Pharmaceuticals | 21.05 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |